A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

This study is currently recruiting participants.
Verified April 2013 by Genentech
Sponsor:
Information provided by (Responsible Party):
Genentech
ClinicalTrials.gov Identifier:
NCT01582503
First received: April 19, 2012
Last updated: April 1, 2013
Last verified: April 2013
  Purpose

This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of 3 dosing regimens of MEMP1972A in patients with allergic asthma who remain inadequately controlled on chronic therapy with high dose inhaled corticosteroids and a second controller medication.Patients will be randomized to 4 Arms to receive subcutaneous repeating dose of either MEMP1972A 150 mg, 300 mg, or 450 mg, or placebo. Patients will continue their usual asthma medication throughout the study. Anticipated time on study treatment is 36 weeks, with a 48-week follow-up.


Condition Intervention Phase
Asthma
Drug: MEMP1972A
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Dosing Regimens of MEMP1972A in Adults With Allergic Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids and a Second Controller (COSTA)

Resource links provided by NLM:


Further study details as provided by Genentech:

Primary Outcome Measures:
  • Rate of protocol-defined asthma exacerbations (new or increased asthma symptoms that lead to treatment with systemic corticosteroids or to hospitalization) from baseline to Week 36 [ Time Frame: 36 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Relative change in pre-bronchodilator FEV1 (volume) [ Time Frame: from baseline to Week 12 ] [ Designated as safety issue: No ]
  • Relative change in FEV1 (volume) [ Time Frame: from baseline to Week 36 ] [ Designated as safety issue: No ]
  • Change in asthma symptoms [ Time Frame: from baseline to Week 12 ] [ Designated as safety issue: No ]
  • Change in asthma symptoms [ Time Frame: from baseline to Week 36 ] [ Designated as safety issue: No ]
  • Proportion of "well-controlled" weeks (no nighttime awakenings due to asthma symptoms and </= 2 days of SABA use per weeks, as documented by patient diary) from Week 24 to Week 36 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Safety: Incidence of adverse events [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Incidence of anti-therapeutic antibodies (ATAs) [ Time Frame: 84 weeks ] [ Designated as safety issue: No ]
  • Pharmacokinetics: Area under the concentration-time curve (AUC) [ Time Frame: Pre- and post-dose Weeks 0, 4, 12, 24 and 36 ] [ Designated as safety issue: No ]

Estimated Enrollment: 560
Study Start Date: April 2012
Estimated Study Completion Date: November 2015
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MEMP1972A 300 mg Drug: MEMP1972A
Subcutaneous repeating dose
Experimental: MEMP1972A 150 mg Drug: MEMP1972A
Subcutaneous repeating dose
Experimental: MEMP1972A 450 mg Drug: MEMP1972A
Subcutaneous repeating dose
Placebo Comparator: Placebo Drug: placebo
Subcutaneous repeating dose

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients, 18 to 75 years of age inclusive
  • Body weight >/= 40 kg
  • Physician's diagnosis of asthma for at least 12 months
  • Evidence of documented bronchodilator reversibility as defined by protocol
  • Prebronchodilator FEV1 >/= 40% and </= 80% predicted at Visit 1
  • Required daily use of ICS and a second controller for a minimum of 3 consecutive months prior to Visit 1
  • History of at least one protocol-defined asthma exacerbation in the 18 months prior to Visit 1
  • Inadequately controlled asthma despite compliance with asthma controller therapy

Exclusion Criteria:

  • Asthma exacerbation requiring systemic steroids in the 30 days prior to Visit 1
  • Pre-existing active lung disease other than asthma
  • Any infection
  • Clinically significant medical disease that is uncontrolled despite treatment or is likely to require a change in therapy during study or is of unknown etiology
  • Known immunodeficiency, including but not limited to HIV infection, regardless of treatment status
  • Current substance abuse
  • Former smoker with >10 pack-year history or current smoker; former smokers must have stopped smoking more than 12 months prior to Visit 1
  • History of anaphylaxis
  • Pregnant and lactating women
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01582503

Contacts
Contact: Please reference Study ID Number: GB27980 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. Only) genentechclinicaltrials@druginfo.com

  Hide Study Locations
Locations
United States, Alabama
Recruiting
Birmingham, Alabama, United States, 35209
United States, California
Recruiting
Bakersfield, California, United States, 93301
Recruiting
Costa Mesa, California, United States, 92626
Recruiting
Fountain Valley, California, United States, 92708
Recruiting
Long Beach, California, United States, 90808
Recruiting
Mission Viejo, California, United States, 92691
Recruiting
Rancho Cordova, California, United States, 95762
Recruiting
Redwood City, California, United States, 94063
Recruiting
Riverside, California, United States, 92506
Recruiting
Stockton, California, United States, 95207
Recruiting
Torrance, California, United States, 90505
United States, Colorado
Recruiting
Centennial, Colorado, United States, 80112
Recruiting
Denver, Colorado, United States, 80206
United States, Connecticut
Recruiting
New Haven, Connecticut, United States, 06520
United States, Florida
Recruiting
Tampa, Florida, United States, 33613
Not yet recruiting
Winter Park, Florida, United States, 32789
United States, Georgia
Recruiting
Albany, Georgia, United States, 31707
United States, Idaho
Recruiting
Twin Falls, Idaho, United States, 83301
United States, Illinois
Recruiting
Normal, Illinois, United States, 61761
Recruiting
River Forest, Illinois, United States, 60305
United States, Iowa
Recruiting
Iowa City, Iowa, United States, 52242
United States, Kansas
Recruiting
Overland Park, Kansas, United States, 66210
United States, Kentucky
Recruiting
Louisville, Kentucky, United States, 40223
United States, Maryland
Recruiting
Baltimore, Maryland, United States, 21236
United States, Missouri
Recruiting
St Louis, Missouri, United States, 63141
Recruiting
St. Louis, Missouri, United States, 63141
United States, Nebraska
Recruiting
Bellevue, Nebraska, United States, 68123
Recruiting
Omaha, Nebraska, United States, 68130
United States, New Jersey
Recruiting
Edison, New Jersey, United States, 08820
Not yet recruiting
Teaneck, New Jersey, United States, 07666
United States, New York
Recruiting
Bronx, New York, United States, 10461
United States, Ohio
Not yet recruiting
Canton, Ohio, United States, 44718
Not yet recruiting
Centerville, Ohio, United States, 45458
Recruiting
Cincinnati, Ohio, United States, 45231
Not yet recruiting
Cleveland, Ohio, United States, 44195
United States, Oklahoma
Recruiting
Oklahoma City, Oklahoma, United States, 73120
Recruiting
Tulsa, Oklahoma, United States, 74136
United States, Oregon
Recruiting
Medford, Oregon, United States, 97504
United States, Pennsylvania
Recruiting
Philadelphia, Pennsylvania, United States, 19140
Recruiting
Pittsburgh, Pennsylvania, United States, 15241
United States, Rhode Island
Recruiting
Providence, Rhode Island, United States, 02906
Recruiting
Warwick, Rhode Island, United States, 02865
United States, South Carolina
Not yet recruiting
Charleston, South Carolina, United States, 29407
United States, Texas
Recruiting
El Paso, Texas, United States, 79903
Recruiting
San Antonio, Texas, United States, 78229
Recruiting
San Antonio, Texas, United States, 78224
Recruiting
Waco, Texas, United States, 76712
United States, Utah
Not yet recruiting
Murray, Utah, United States, 84107
United States, Virginia
Recruiting
Springfield, Virginia, United States, 22152
United States, Washington
Recruiting
Spokane, Washington, United States, 99204
United States, Wisconsin
Recruiting
Greenfield, Wisconsin, United States, 53228
Argentina
Recruiting
Buenos Aires, Argentina, 1186
Recruiting
Buenos Aires, Argentina, 1056
Recruiting
Ciudad Autónoma de Buenos Air, Argentina, C1425BEN
Not yet recruiting
Florencio Varela, Argentina, B1878DVB
Not yet recruiting
Mendoza, Argentina, 5500
Recruiting
Quilmes, Argentina, 1878
Recruiting
Rosario, Argentina, 2000
Recruiting
Salta, Argentina, 4400
Recruiting
San Miguel de Tucuman, Argentina, 4000
Not yet recruiting
Tucuman, Argentina, 4000
Belgium
Recruiting
Halen, Belgium, 3545
Recruiting
Jambes, Belgium, 5100
Recruiting
Leuven, Belgium, 3000
Brazil
Not yet recruiting
Belo Horizonte, Brazil, 30150-221
Not yet recruiting
Florianopolis, Brazil, 88040-970
Not yet recruiting
Porto Alegre, Brazil, 90610-000
Not yet recruiting
Porto Alegre, Brazil, 90020-090
Not yet recruiting
Porto Alegre, Brazil, 91350-200
Not yet recruiting
Rio de Janeiro, Brazil, 22280-010
Not yet recruiting
Rio de Janeiro, Brazil, 20551-030
Not yet recruiting
Salvador, Brazil, 41940-455
Not yet recruiting
Santo Andre, Brazil, 09060-050
Not yet recruiting
Sao Paulo, Brazil, 05403-900
Not yet recruiting
Sao Paulo, Brazil, 04023-062
Not yet recruiting
Sao Paulo, Brazil, 05437-010
Bulgaria
Recruiting
Pleven, Bulgaria, 5800
Not yet recruiting
Plovdiv, Bulgaria, 4003
Recruiting
Ruse, Bulgaria, 7002
Recruiting
Sofia, Bulgaria, 1606
Recruiting
Sofia, Bulgaria, 1233
Recruiting
Sofia, Bulgaria, 1431
Not yet recruiting
Sofia, Bulgaria, 1336
Not yet recruiting
Sofia, Bulgaria, 1680
Not yet recruiting
Sofia, Bulgaria, 1431
Recruiting
Stara Zagora, Bulgaria, 6003
Recruiting
Varna, Bulgaria, 9010
Canada, British Columbia
Recruiting
Vancouver, British Columbia, Canada, V5Z 1M9
Canada, Ontario
Recruiting
Mississauga, Ontario, Canada, L5A 3V4
Recruiting
Ottawa, Ontario, Canada, K1Y 4G2
Recruiting
Toranto, Ontario, Canada, M5T 3A9
Recruiting
Toronto, Ontario, Canada, M6H 3M2
Recruiting
Toronto, Ontario, Canada, M4V 1R2
Germany
Recruiting
Berlin, Germany, 14050
Recruiting
Berlin, Germany, 10117
Recruiting
Bochum, Germany, 44791
Recruiting
Coswig, Germany, 01640
Recruiting
Freiburg, Germany, 79106
Recruiting
Geesthacht, Germany, 21502
Recruiting
Jena, Germany, 07740
Recruiting
Landsberg, Germany, 86899
Recruiting
Magdeburg, Germany, 39120
Recruiting
Mainz, Germany, 55131
Recruiting
Muenster, Germany, 48149
Hungary
Recruiting
Balassagyarmat, Hungary, 2660
Recruiting
Debrecen, Hungary, 4043
Recruiting
Mosonmagyaróvar, Hungary, 9200
Mexico
Recruiting
Guadalajara, Mexico, 44130
Recruiting
Mexico, Mexico, 03100
Recruiting
Nuevo Leon, Mexico, 64710
New Zealand
Recruiting
Auckland, New Zealand, 1023
Recruiting
Auckland, New Zealand, 2025
Recruiting
Christchurch, New Zealand, 8011
Recruiting
Dunedin, New Zealand
Recruiting
Hamilton, New Zealand
Recruiting
Wellington, New Zealand
Peru
Not yet recruiting
Lima, Peru, Lima 21
Not yet recruiting
Lima, Peru, Lima 41
Not yet recruiting
Lima, Peru, Lima 07
Not yet recruiting
Lima, Peru, Lima 33
Not yet recruiting
Lima, Peru, 31
Not yet recruiting
Lima, Peru, Lima 27
Not yet recruiting
Lima, Peru, LIMA 29
Not yet recruiting
Lima, Peru, Lima 1
Not yet recruiting
Miraflores, Peru, Lima 18
Not yet recruiting
Piura, Peru
Poland
Recruiting
Bialystok, Poland, 15-003
Recruiting
Bialystok, Poland, 15-950
Recruiting
Bialystok, Poland, 15-010
Recruiting
Katowice, Poland, 40-752
Recruiting
Kielce, Poland, 25-734
Recruiting
Krakow, Poland, 31-023
Recruiting
Lublin, Poland, 20-552
Recruiting
Poznan, Poland, 60-214
Recruiting
Skierniewice, Poland, 96-100
Recruiting
Tarnow, Poland, 33-100
Recruiting
Warszawa, Poland, 01-868
Recruiting
Wroclaw, Poland, 54-239
Romania
Recruiting
Brasov, Romania, 500283
Recruiting
Brasov, Romania, 16
Recruiting
Bucharest, Romania, 050159
Recruiting
Bucuresti, Romania, 011426
Recruiting
Bucuresti, Romania, 020125
Recruiting
Cluj-napoca, Romania, 400349
Recruiting
Craiova, Romania, 200515
Recruiting
Deva, Romania, 330084
Russian Federation
Recruiting
Moscow, Russian Federation, 117292
Recruiting
S. Petersburg, Russian Federation, 195067
Recruiting
Smolensk, Russian Federation, 214006
Recruiting
St Petersburg, Russian Federation, 193231
Recruiting
St. Petersburg, Russian Federation, 194354
Ukraine
Not yet recruiting
Dnepropetrovsk, Ukraine, 49071
Recruiting
Dnipropetrovsk, Ukraine, 49066
Not yet recruiting
Ivano-frankivsk, Ukraine, 76018
Not yet recruiting
Kiev, Ukraine, 03680
Not yet recruiting
Kyiv, Ukraine, 03680
Not yet recruiting
Kyiv, Ukraine, 02232
Not yet recruiting
Lviv, Ukraine, 79010
Not yet recruiting
Odessa, Ukraine, 65114
Sponsors and Collaborators
Genentech
Investigators
Study Director: Clinical Trials Genentech
  More Information

No publications provided

Responsible Party: Genentech
ClinicalTrials.gov Identifier: NCT01582503     History of Changes
Other Study ID Numbers: GB27980, 2011-003997-10
Study First Received: April 19, 2012
Last Updated: April 1, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on May 23, 2013